⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2007HaematologicaOpen Access

Fc RIIIA and Fc RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab

Emanuela Carlotti Giuseppe A. Palumbo Elena Oldani Daniele Tibullo Silvia Salmoiraghi A. Rossi Josée Golay Alessandro Pulsoni R. Foà Alessandro Rambaldi

View Full Paper

Ask AI

Bookmark

Share

Abstract

We analyzed FcgammaRIIIA-158V/F and FcgammaRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcgammaRIIIA-158VV/VF and FcgammaRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Carlotti et al. (2007) studied this question.

synapsesocial.com/papers/6a211fee1e2099cdfc9d0d44 https://doi.org/10.3324/haematol.11288

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Venetoclax plus azacitidine in younger adults with acute myeloid leukemia beyond historical comparisons. Comment on: "Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy"Haematologica · Thu,
2Effects of secondary factor VIII prophylaxis on joint and bone health in a hemophilia A mouse modelHaematologica · Thu,
3Response to Comment on: “Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications”Haematologica · Thu,
4Hyperinflammatory differentiation syndrome with hemophagocytic lymphohistiocytosis-like features following menin inhibition in acute myeloid leukemiaHaematologica · Thu,
5Cord blood-derived natural killer cells engineered with a novel, highaffinity chimeric antigen receptor can eliminate acute myeloid leukemia cells with minimal C-type lectin-like molecule-1 expressionHaematologica · Thu,

More from Haematologica

Is hematopoietic stem cell transplantation indicated in THPO-mutated congenital amegakaryocytic thrombocytopenia? Comment on: "Avatrombopag as a novel salvage therapy for refractory thrombocytopenia in THPO-mutated congenital amegakaryocytic thrombocytopenia after allogeneic hematopoietic stem cell transplantation"Thu,
Metronomic decitabine with venetoclax offers a patient-centered frontline therapeutic approach for TP53-mutated complex-karyotype myeloid neoplasmsThu,
Outcomes of ibrutinib plus lenalidomide combination in patients with large Bcell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T studyThu,
Neutrophil extracellular traps and DNase I levels in the bronchoalveolar lavage fluid of children with pulmonary injury after allogeneic hematopoietic stem cell transplantation: a TRANSPIRE studyThu,
Beyond exclusion: the case for genetic screening in immune thrombocytopeniaThu,